5-lipoxygenase activating protein (FLAP) inhibitor. Inhibits the synthesis of leukotrienes B4
in animal models; inhibits synthesis of leukotriene B4
in A23187-stimulated leukocytes (IC50
values are 0.026, 0.039 and 0.22 μ
M for rat, mice and human leukocytes respectively). Displays anti-inflammatory activity. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
Muller-Peddinghaus et al.
Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.
Hatzelmann et al.
Agents Actions, 1994;43:64
In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.
Fruchtmann et al.
Agents Actions, 1993;38:188